Abstract
In April 2020, we developed a COVID-19 transmission model used as part of RAND’s web-based COVID-19 decision support tool that compares the effects of different nonphar-maceutical public health interventions (NPIs) on health and economic outcomes. An interdis-ciplinary approach informed the selection and use of multiple NPIs, combining quantitative modeling of the health/economic impacts of interventions with qualitative assessments of other important considerations (e.g., cost, ease of implementation, equity). We previously published a description of our approach as a RAND report describing how the epidemiological model, the economic model, and a systematic assessment of NPIs informed the web-tool. This paper provides further details of our model, describes extensions that we made to our model since April, presents sensitivity analyses, and analyzes periodic NPIs. Our findings suggest that there are opportunities to shape the tradeoffs between economic and health outcomes by carefully evaluating a more comprehensive range of reopening policies. We consider strategies that periodically switch between a base NPI level and a higher NPI level as our working example.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This project was internally funded by RAND. We also thank the National Cancer Institute (R21CA157571), and the National Institute of Allergies and Infectious Diseases (R01AI118705) for providing support in projects that led to preliminary work and ideas that motivated this project.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
In this modeling study we only used secondary de-identified data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All modeling data is available upon request.
